Bisoprolol (versus unexposed) updated on 12-17-2024

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17245
R72169		 Vaclavik, 2024 Low birth weight during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 2.12 [1.60;2.81] -/55   -/66,393 - 55
ref
S14242
R55945		 Ishibashi, 2017 Low birthweight infants (birth weight less than 2500 kg) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 18.25 [3.43;97.17] C 7/9   14/87 21 9
ref
Total 2 studies 5.28 [0.66;42.46] 21 64
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vaclavik, 2024Vaclavik, 2024 2.12[1.60; 2.81]-5558%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: unclear Ishibashi, 2017Ishibashi, 2017 18.25[3.43; 97.17]21942%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: low Total (2 studies) I2 = 84% 5.28[0.66; 42.46]21640.950.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 5.28[0.66; 42.46]216484%NAVaclavik, 2024 Ishibashi, 2017 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.12[1.60; 2.81]-55 -NAVaclavik, 2024 1 unexposed, sickunexposed, sick 18.25[3.43; 97.17]219 -NAIshibashi, 2017 1 Tags Adjustment   - No  - No 5.28[0.66; 42.46]216484%NAVaclavik, 2024 Ishibashi, 2017 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 2.12[1.60; 2.81]-55 -NAVaclavik, 2024 1   - Only cardiac indications other than ...  - Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 18.25[3.43; 97.17]219 -NAIshibashi, 2017 1 All studiesAll studies 5.28[0.66; 42.46]216484%NAVaclavik, 2024 Ishibashi, 2017 20.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.12[1.60; 2.81]-55 -NAVaclavik, 2024 1 unexposed, sick controlsunexposed, sick controls Out of scale18.25[3.43; 97.17]219 -NAIshibashi, 2017 10.510.01.0